EDiX

EDiX Therapeutics is a biotechnology company focused on developing a novel class of therapeutics by targeting the epitranscriptome. The company leverages its proprietary platform to modulate RNA modifications, such as RNA methylation, to treat a variety of diseases including cancer and neurological disorders. By focusing on RNA-binding proteins and the enzymes that modify RNA, EDiX aims to address targets that have historically been considered undruggable. The company's approach represents a significant shift from traditional gene editing, offering a reversible and potentially safer method of regulating gene expression at the post-transcriptional level.